Skip to content
ClinCalc Pro
Menu
Antibiotic (Aminoglycoside)

Gentamicin

Brand names: Cidomycin, Genticin

Gentamicin is an aminoglycoside antibiotic used for serious Gram-negative infections and surgical prophylaxis, often in combination with other agents.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds irreversibly to the bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis, producing a concentration-dependent bactericidal effect.

Prescribing in practice

  • Nephrotoxicity and ototoxicity (vestibular and auditory) are the principal hazards and may be irreversible; use the lowest effective course and monitor closely, with particular caution in renal impairment and the elderly.
  • Dosing is weight- and renal-function-based; consult local protocols and current prescribing references for the regimen and any therapeutic drug monitoring requirements.
  • Avoid concurrent use with other nephrotoxic or ototoxic drugs, including loop diuretics, where possible.

Monitoring

Monitor renal function and serum gentamicin concentrations per local protocol, and assess for auditory or vestibular symptoms during prolonged therapy.

Counselling the patient

  • Report any new hearing loss, ringing in the ears, dizziness or unsteadiness promptly.
  • Maintain adequate hydration and tell the team about any kidney problems.

Evidence & guidelines

Aminoglycoside use is well established for serious Gram-negative sepsis and surgical prophylaxis, with MHRA and NICE guidance emphasising monitoring to limit nephro- and ototoxicity.

Reference: BSAC Aminoglycoside Guidelines; Hartford OD Nomogram; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.